Sydnexis — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Sydnexis is a private, pre-revenue biotech company founded in 2019 to tackle the growing epidemic of pediatric progressive myopia, the leading cause of vision loss in children. The company's lead asset, SYD-101, is an investigational low-dose atropine eye drop currently in Phase 3 development, with topline data from its pivotal STAR study announced in late 2025. Sydnexis aims to commercialize the first pharmaceutical treatment specifically engineered for young children with PPM, leveraging a large and urgent unmet medical need driven by rising global myopia rates. The company has established a key partnership with Santen, which has gained UK approval for a related product.

OphthalmologyPediatric Myopia

Technology Platform

Proprietary formulation and development of low-dose atropine eye drops specifically engineered for pediatric use to slow axial elongation in progressive myopia.

Opportunities

The global epidemic of pediatric myopia creates a vast and growing addressable market for a first-in-class pharmaceutical treatment.

High parental concern and motivation to prevent progression, combined with limited suitable options for young children, provide a strong foundation for rapid adoption upon approval.

The partnership with Santen offers commercial validation, near-term revenue potential, and a template for expansion into other regions.

Risk Factors

The company faces significant regulatory risk, as the FDA and other agencies will scrutinize long-term safety data in a pediatric population.

Commercial success depends on achieving favorable reimbursement and displacing established standards of care (glasses) and emerging competitors like specialty contact lenses.

Execution risk is high as a private biotech navigating the final stages of development and potential launch.

Competitive Landscape

Competition includes refractive correction (glasses, standard contacts), medical devices like CooperVision's FDA-approved MiSight® soft contact lens, and off-label/compounded low-dose atropine. Sydnexis aims to differentiate by targeting a younger patient population (as young as 3) with a convenient, standardized, and regulatorily-approved pharmaceutical eye drop, a niche not currently served by approved products.

More companies in Small Molecule Drugs →More companies in United States →